In summary, these findings indicate the high utility of measuring pNfH and NfL in serum or CSF as biomarkers for monitoring SMA onset, disease progression, and response to therapy, preferably in the youngest SMA patients who have no more than three SMN2 copies. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.